Description
Pelitinib is an irreversible EFGR inhibitor that exhibits anticancer chemotherapeutic benefit in the treatment of non-small cell lung cancer (NSCLC) and other solid tumor cancers. In vitro, pelitinib inhibits NF-κB, inhibiting transcription of TERT and telomerase activity. Pelitinib also decreases phosphorylation of Akt and ERK and induces cell cycle arrest in vitro.